Early SBRT Before Chemoimmunotherapy Shows Promise in Borderline Resectable and Locally Advanced Pancreatic Cancer
1h agoen
From the article
Pancreatic cancer remains one of the most difficult malignancies to treat, particularly when patients present with borderline resectable or locally advanced disease. In these cases, surgery is often not immediately […]
Continue reading on OncoDailyYou might also wanna read
SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer
clinicaltrials.gov·3d ago
Tumor-on-a-Chip Reveals How Pancreatic Cancer Hijacks Immune Cells
Medbound·1d ago
New Drug Shows Promise in Penetrating Pancreatic Cancer's 'Fibrotic Fortress'
Pancreatic cancer has an extremely low survival rate (97% mortality within 5 years for metastatic cases) due to late detection and the forma
sciencealert.com·29d ago
Spanish Researchers Develop Breakthrough Therapy Protocol for Pancreatic Cancer Treatment
Spanish researchers have developed a new therapy protocol that could revolutionize pancreatic cancer treatment. Pancreatic cancer is notorio
nypost.com·5mo ago
New cancer drug trial offers hope for patients with rare aggressive tumour
Reading Chronicle·2d ago
Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer | NEJM
nejm.org·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.